JP2023500574A5 - - Google Patents

Info

Publication number
JP2023500574A5
JP2023500574A5 JP2022520769A JP2022520769A JP2023500574A5 JP 2023500574 A5 JP2023500574 A5 JP 2023500574A5 JP 2022520769 A JP2022520769 A JP 2022520769A JP 2022520769 A JP2022520769 A JP 2022520769A JP 2023500574 A5 JP2023500574 A5 JP 2023500574A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
chimeric molecule
molecule according
tmmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500574A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056908 external-priority patent/WO2021081239A1/en
Publication of JP2023500574A publication Critical patent/JP2023500574A/ja
Publication of JP2023500574A5 publication Critical patent/JP2023500574A5/ja
Pending legal-status Critical Current

Links

JP2022520769A 2019-10-23 2020-10-22 T細胞調節性キメラ分子及びその使用方法 Pending JP2023500574A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962925115P 2019-10-23 2019-10-23
US62/925,115 2019-10-23
PCT/US2020/056908 WO2021081239A1 (en) 2019-10-23 2020-10-22 T-cell modulatory chimeric molecules and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023500574A JP2023500574A (ja) 2023-01-10
JP2023500574A5 true JP2023500574A5 (cg-RX-API-DMAC7.html) 2023-10-25

Family

ID=75620861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520769A Pending JP2023500574A (ja) 2019-10-23 2020-10-22 T細胞調節性キメラ分子及びその使用方法

Country Status (8)

Country Link
US (2) US20230055644A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048689A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023500574A (cg-RX-API-DMAC7.html)
CN (1) CN114599674A (cg-RX-API-DMAC7.html)
AU (1) AU2020370292A1 (cg-RX-API-DMAC7.html)
CA (1) CA3146917A1 (cg-RX-API-DMAC7.html)
IL (1) IL290298A (cg-RX-API-DMAC7.html)
WO (1) WO2021081239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808552XA (en) * 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3897746A4 (en) * 2018-12-19 2022-10-26 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法
EP4504802A4 (en) * 2022-04-07 2026-03-25 Cue Biopharma Inc IMMUNE CELL BINDING POLYPEPTIDES
GB202205771D0 (en) * 2022-04-20 2022-06-01 Replay Holdings Llc Methods and compositions for cellular therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2178896A1 (en) * 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
JP6652932B2 (ja) * 2014-06-18 2020-02-26 アルバート アインシュタイン カレッジ オブ メディシン synTacポリペプチド及びその使用
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
KR20240005989A (ko) * 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2019051127A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
JP2023500573A5 (cg-RX-API-DMAC7.html)
JP2022534846A5 (cg-RX-API-DMAC7.html)
JP2025037871A5 (cg-RX-API-DMAC7.html)
JP2023518049A5 (cg-RX-API-DMAC7.html)
KR102528977B1 (ko) 펩타이드-hla 복합체 및 그 제조 방법
JP2021536265A5 (cg-RX-API-DMAC7.html)
JP2021525509A5 (cg-RX-API-DMAC7.html)
JP2022515331A5 (cg-RX-API-DMAC7.html)
EP3169703B2 (en) Chimeric antigen receptor and its use
Fremont et al. Biophysical studies of T-cell receptors and their ligands
JP2019518424A5 (cg-RX-API-DMAC7.html)
NZ759969A (en) Tagged chimeric effector molecules and receptors thereof
JP2022552314A5 (cg-RX-API-DMAC7.html)
KR20180057720A (ko) 다가 Fv 항체
JP2018525033A5 (cg-RX-API-DMAC7.html)
RU2018134771A (ru) Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение
JP2019513347A5 (cg-RX-API-DMAC7.html)
JP2022536581A5 (cg-RX-API-DMAC7.html)
JP2017501702A5 (cg-RX-API-DMAC7.html)
JP2021534740A5 (cg-RX-API-DMAC7.html)
JP2019535262A5 (cg-RX-API-DMAC7.html)
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
WO2012031744A1 (en) Chimeric antigen receptors with an optimized hinge region
JP2021532742A5 (cg-RX-API-DMAC7.html)
WO2016184592A1 (en) T cell receptor with specificity for myeloperoxidase peptide and uses thereof